期刊文献+

FLAG方案治疗难治及复发急性淋巴细胞白血病13例

原文传递
导出
摘要 目的观察氟达拉滨(Flu)、阿糖胞苷(Ara—C)及粒细胞集落刺激因子(G—CSF)(FLAG方案)治疗复发及难治性急性淋巴细胞白血病(ALL)的临床疗效及安全性。方法对13例复发及难治性ALL患者给予1~3个疗程FLAG方案化疗,观察其疗效及患者不良反应。结果FLAG方案治疗总有效(OR)率为76.92%(10/13)。患者主要不良反应为骨髓抑制和继发感染。结论FLAG方案对于复发及难治性ALL患者是一种有效的治疗选择,不良反应大多能够耐受。
作者 严红 赵海军
出处 《白血病.淋巴瘤》 CAS 2011年第9期559-560,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献8

  • 1Aviv I,Irit R,Jacob M,et al.Acute lymphocytic leukemia:role of hematopoietic stem cell transplantation in current management.Curr Opin Hematol,2003,10:463-468. 被引量:1
  • 2张之南,沈悌主编..血液病诊断及疗效标准 第3版[M].北京:科学出版社,2007:271.
  • 3Genini D,Budihardjo I,Plunkett W,et al.Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-l-mediated pathway.J Biol Chom,2000,275:29-34. 被引量:1
  • 4McCarthy AJ,Pitcher LA,Hann IM,et al.FLAG (fludarabine,highdose cytarabine,and G-CSF) for refractory and high-risk relapsed acute leukemia in children.Med Pediatr Oncol,1999,32:411-415. 被引量:1
  • 5黄晓军,路瑾,陆道培.氟达拉滨为主方案治疗难治复发急性白血病[J].中华内科杂志,2003,42(6):417-419. 被引量:18
  • 6孟凡义,徐兵,杜欣,汪明春,朱康儿.氟达拉滨联合不同剂量阿糖胞苷治疗复发、难治性急性白血病86例分析[J].中华血液学杂志,2006,27(6):419-420. 被引量:14
  • 7Yalman N,Sarper N,Devecioglu O,et al.Fludarabine,cytarabine,GCSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.Turk J Pediatr,2000,42:198-204. 被引量:1
  • 8Montillo M,Mirto S,Petti MC,et al.Fludarabine,cytarabine,and GCSF (FLAG) for the treatment of poor risk acute myeloid leukemia.Am J Hematol,1998,58:5-9. 被引量:1

二级参考文献9

  • 1Belhabri A,Thomas X,Wattel E,et al.All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia:a phase Ⅱ randomized trial.Hematol J,2002,3:49-55. 被引量:1
  • 2Gandni V,Estey E,Keating M J,et al.Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.J Clin Oncol,1993,11:116-124. 被引量:1
  • 3Weiss L,Abdul-Hai A,Or R,et al.Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia.Bone Marrow Transplant,2003,31:11-15. 被引量:1
  • 4McCarthy A J,Pitcher LA,Hann IM,et al.FLAG (fludarabine,high-dose cytarabine,and G-CSF) for refractory and high-risk relapsed acute leukemia in children.Med Pediatr Oncol,1999,32:411-415. 被引量:1
  • 5Montillo M,Mirto S,Petti MC,et al.Fludarabine,cytarabine,and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.Am J Hematol,1998,58:105-109. 被引量:1
  • 6Yalman N,Sarper N,Devecioglu O,et al.Fludarabine,cytarabine,G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.Turk J Pediatr,2000,42:198-204. 被引量:1
  • 7Ferrara F,Palmieri S,Pocali B,et al.De novo acute myeloid leukemia with multilineage dysplasia:treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine,cytarabine and G-CSF (FLAG).Eur J Haematol,2002,68:203-209. 被引量:1
  • 8Visani G,Tosi P,Zinzani PL,et al.FLAG (fludarabine + high-dose+ G-CSF):an effective and tolerable protocol for the treatment of"poor risk" acute myeloid leukemia.Leukemia,1994,8:1842-1846. 被引量:1
  • 9Jackson G,Taylor P,Smith GM,et al.A multicentre,open,noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.Br J Haematol,2001,112:127-137. 被引量:1

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部